Replies to post #433874 on Amarin Corp Plc (AMRN)

[rosemountbomber]

For this to make any sense Q1 EU would absolutely have to be great.  If not then there is a foul smell in Denmark. 

And you are right about the US jump from Q3 to Q4.  The company would have definitely said something if scripts had really jumped in the qtr

[north40000]

Regarding Q3(assuming that is 7/1--9/30 2024), that is when Amarin lost the CVS/Caremark account, losing the supply contract and formulary position to the generics like Hikma and Dr. Reddy. My insurance company, 7/1, had sold its Vascepa coverage business. I wound up paying > $1000 for a 3-month refill for Vascepa rather than the Dr. Reddy formulation then on CVS shelves. My standard DAW scrip for Vascepa from my PCP "somehow had been erased" from CVS pharmacy computer files, and I was given a Dr. Reddy product instead(3 bottles of capsules wrapped in a stapled brown paper bag). I returned 2 bottles of Dr. Reddy product, kept 1 bottle with label and encapsulated product for later use as evidence of collusive healthcare fraud.

 I later refilled a new DAW scrip for Vascepa, still at a much higher comparative price than the co-pay price of $9-15 I had paid for years prior to 7/1/2024.

The physical evidence, capsules, receipts, etc., will be sent FTC Chair Ferguson and/or Attorney General this coming week, along with photocopy pages from our shareholder Petition for Writ of Certiorari in the Nevada Hikma/DRL matter, 7/1/2024 letter from insurance company, copy of CAFC opinion reversing D.Delaware judge  in Hikma v. Amarin, and other evidence.

The FTC chair, even this morning when interviewed by a CNBC reporter, has made it clear he intends to use his resources to protect the American population from collusive fraud, particularly in the pharmaceutical industry. H and DRL do not belong as competitors in any aspect of Amarin's high triglycerides or CVD businesses, IMO. Their products should be banned from distribution and sale.

[rosemountbomber]

2. WHAT is going on in Europe?? How are revenues flat/down from Q3 to Q4? That seems illogical. Is this again some sort of timing issue, and Q1 will look great?

Regardless that the numbers from the EU are somehow affected by timing or other factors, it is still rather depressing looking at the uptake. Mind you, we don't have the 2 biggies - France and Germany - so that factors into it. But, my molasses in winter seems to move faster. What is the most frustrating for me (and possibly other old timers) is that I can remember management (not this current crew) talk about how Europe was a multi-billion dollar opportunity. There must have been a reason why the market, even back in the glory days, did not factor that story into the market cap.

[Birdbrain Ideas]

On the European sales, I wonder if the drop in sales in the Fourth Quarter reflects the fact that sometimes the company seems to claim sales when it ships its product, rather than when the product reaches its endpoint. Am I right about that? So perhaps the drop reflects that they've begun to stick with actual sales to the consumer. Meanwhile, I'm curious why RoW sales ballooned from $6.9 million in the Third Quarter to $11.9 million in the Fourth. A doubling in sales in a single quarter? What does that reflect? Did it come up at the earnings call? Wouldn't they be trumpeting that? Or was it another blip. And the licensing revenues quadrupled? But then I saw this in the earnings transcript: It is important to note that in the current year, product revenue with our partners includes supply shipments in preparation for market launches. Our partnership revenue can be variable quarter to quarter and year to year based on restocking timing relative to end-market demand.